Rxcurve
HCPCS J9349 · per 2 MG

Inj., tafasitamab-cxix

Products billed under this code include Monjuvi.

Payment limit per 2 MG, by effective quarter, 2Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J9349

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Monjuvi Incyte Corporation 50881-0013-03 100 $1,442.80
Monjuvi Incyte Corporation 73535-0208-01 100 $1,442.80

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $14.428 −$0.001 2 MG Inj., tafasitamab-cxix v1, posted September 17, 2026
3Q26 $14.429 +$0.263 2 MG Inj., tafasitamab-cxix v1, posted September 15, 2026
2Q26 $14.166 −$0.076 2 MG Inj., tafasitamab-cxix v1, posted September 15, 2026
1Q26 $14.242 −$0.069 2 MG Inj., tafasitamab-cxix v1, posted September 15, 2026
4Q25 $14.311 +$0.236 2 MG Inj., tafasitamab-cxix v1, posted September 8, 2026
3Q25 $14.075 +$0.15 2 MG Inj., tafasitamab-cxix v1, posted March 10, 2026
2Q25 $13.925 −$0.041 2 MG Inj., tafasitamab-cxix v1, posted March 10, 2026
1Q25 $13.966 +$0.257 2 MG Inj., tafasitamab-cxix v1, posted December 19, 2025
4Q24 $13.709 −$0.066 2 MG Inj., tafasitamab-cxix v1, posted June 11, 2025
3Q24 $13.775 +$0.197 2 MG Inj., tafasitamab-cxix v1, posted June 11, 2025
2Q24 $13.578 −$0.018 2 MG Inj., tafasitamab-cxix v1, posted March 11, 2025
1Q24 $13.596 +$0.308 2 MG Inj., tafasitamab-cxix v1, posted December 19, 2024
4Q23 $13.288 −$0.014 2 MG Inj., tafasitamab-cxix v1, posted October 10, 2024
3Q23 $13.302 +$0.151 2 MG Inj., tafasitamab-cxix v1, posted June 5, 2024
2Q23 $13.151 +$0.003 2 MG Inj., tafasitamab-cxix v1, posted February 23, 2024
1Q23 $13.148 +$0.18 2 MG Inj., tafasitamab-cxix v1, posted December 6, 2023
4Q22 $12.968 +$0.003 2 MG Inj., tafasitamab-cxix v1, posted June 22, 2023
3Q22 $12.965 +$0.183 2 MG Inj., tafasitamab-cxix v1, posted June 9, 2023
2Q22 $12.782 −$0.018 2 MG Inj., tafasitamab-cxix v1, posted December 14, 2022
1Q22 $12.80 +$0.181 2 MG Inj., tafasitamab-cxix v1, posted June 8, 2022
4Q21 $12.619 −$0.019 2 MG Inj., tafasitamab-cxix v1, posted June 2, 2022
3Q21 $12.638 −$0.023 2 MG Inj., tafasitamab-cxix v1, posted June 2, 2022
2Q21 $12.661 – 2 MG Inj., tafasitamab-cxix v1, posted March 1, 2022

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files